美国 - 英文 - NLM (National Library of Medicine)

pai holdings, llc - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt) - atovaquone oral suspension usp is indicated for the prevention of pneumocystis jirovecii pneumonia (pcp) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (tmp-smx). atovaquone oral suspension usp is indicated for the acute oral treatment of mild-to-moderate pcp in adults and adolescents (aged 13 years and older) who cannot tolerate tmp-smx. clinical experience with atovaquone oral suspension usp for the treatment of pcp has been limited to subjects with mild-to-moderate pcp (alveolar-arterial oxygen diffusion gradient [(a-a)do 2 ] ≤45 mm hg). treatment of more severe episodes of pcp with atovaquone oral suspension usp has not been studied. the efficacy of atovaquone oral suspension usp in subjects who are failing therapy with tmp-smx has also not been studied. atovaquone oral suspension is contraindicated in p

美国 - 英文 - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt) - atovaquone oral suspension is indicated for the prevention of pneumocystis jirovecii pneumonia (pcp) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (tmp-smx). atovaquone oral suspension is indicated for the acute oral treatment of mild-to-moderate pcp in adults and adolescents (aged 13 years and older) who cannot tolerate tmp-smx. clinical experience with atovaquone for the treatment of pcp has been limited to subjects with mild-to-moderate pcp (alveolar-arterial oxygen diffusion gradient [(a-a)do2 ] ≤45 mm hg). treatment of more severe episodes of pcp with atovaquone has not been studied. the efficacy of atovaquone in subjects who are failing therapy with tmp-smx has also not been studied. atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension. pregnancy category

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - atovaquone, quantity: 250 mg; proguanil hydrochloride, quantity: 100 mg - tablet - excipient ingredients: povidone; microcrystalline cellulose; poloxamer; sodium starch glycollate type a; hyprolose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 8000; iron oxide red; macrogol 400 - promozio (250mg atovaquone/100mg proguanil hydrochloride) is indicated for:,? prophylaxis of plasmodium falciparum malaria in adults.,? treatment of plasmodium falciparum malaria in adults.

加拿大 - 英文 - Health Canada

teva canada limited - atovaquone; proguanil hydrochloride - tablet - 250mg; 100mg - atovaquone 250mg; proguanil hydrochloride 100mg - antimalarials

加拿大 - 英文 - Health Canada

mylan pharmaceuticals ulc - atovaquone; proguanil hydrochloride - tablet - 250mg; 100mg - atovaquone 250mg; proguanil hydrochloride 100mg - antimalarials

美国 - 英文 - NLM (National Library of Medicine)

glaxosmithkline llc - atovaquone (unii: y883p1z2lt) (atovaquone - unii:y883p1z2lt) - atovaquone 750 mg in 5 ml - mepron oral suspension is indicated for the prevention of pneumocystis jirovecii pneumonia (pcp) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (tmp-smx). mepron oral suspension is indicated for the acute oral treatment of mild-to-moderate pcp in adults and adolescents (aged 13 years and older) who cannot tolerate tmp-smx. clinical experience with mepron for the treatment of pcp has been limited to subjects with mild-to-moderate pcp (alveolar-arterial oxygen diffusion gradient [(a-a)do2 ] ≤45 mm hg). treatment of more severe episodes of pcp with mepron has not been studied. the efficacy of mepron in subjects who are failing therapy with tmp-smx has also not been studied. mepron oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of mepron. risk summary available data from postmarketing experience with

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

generics (uk) limited - atovaquone ; proguanil hydrochloride - film coated tablet - 250/100 milligram - proguanil, combinations

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

glenmark pharmaceuticals europe limited - atovaquone; proguanil hydrochloride - film-coated tablet - 250 mg/100 milligram(s) - biguanides; proguanil, combinations

加拿大 - 英文 - Health Canada

sanis health inc - atovaquone; proguanil hydrochloride - tablet - 250mg; 100mg - atovaquone 250mg; proguanil hydrochloride 100mg - antimalarials

加拿大 - 英文 - Health Canada

glenmark pharmaceuticals canada inc. - atovaquone; proguanil hydrochloride - tablet - 250mg; 100mg - atovaquone 250mg; proguanil hydrochloride 100mg - antimalarials